Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Dow
Moodys
McKesson
McKinsey
Mallinckrodt
AstraZeneca

Last Updated: January 31, 2023

Investigational Drug Information for Mavoglurant


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for Mavoglurant?

Mavoglurant is an investigational drug.

There have been 6 clinical trials for Mavoglurant. The most recent clinical trial was a Phase 2 trial, which was initiated on August 17th 2017.

The most common disease conditions in clinical trials are Alcoholism, Cocaine-Related Disorders, and Syndrome. The leading clinical trial sponsors are Yale University, Novartis Pharmaceuticals, and Elizabeth Berry-Kravis.

There are fifty-five US patents protecting this investigational drug and five hundred and eighty-five international patents.

Recent Clinical Trials for Mavoglurant
TitleSponsorPhase
Functional Neuroimaging of Alcoholism Vulnerability: Probing Glutamate and Reward, Using the mGluR5 Inhibitor MavoglurantYale UniversityEarly Phase 1
Metabotropic Glutamate Receptor-5 (mGlur5) Effects on Reward-Related fMRI-BOLD Activation in FHP and FHNYale UniversityEarly Phase 1
Mavoglurant in Alcohol DrinkingYale UniversityPhase 1

See all Mavoglurant clinical trials

Clinical Trial Summary for Mavoglurant

Top disease conditions for Mavoglurant
Top clinical trial sponsors for Mavoglurant

See all Mavoglurant clinical trials

US Patents for Mavoglurant

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Mavoglurant See Plans and Pricing Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) See Plans and Pricing
Mavoglurant See Plans and Pricing Methods of treating sleep disorders Melior Pharmaceuticals II, LLC (Exton, PA) See Plans and Pricing
Mavoglurant See Plans and Pricing Composition and method for treating neurological disease Osmotica Kereskedelmi es Szolgaltato Korlatolt Feleossegu Tarsasag (Budapest, HU) See Plans and Pricing
Mavoglurant See Plans and Pricing Composition and method for treating neurological disease Osmotica Kereskedelmi es Szolgaltato Korlatolt Felelossegu Tarsasag (Budapest, HU) See Plans and Pricing
Mavoglurant See Plans and Pricing Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Mavoglurant

Drugname Country Document Number Estimated Expiration Related US Patent
Mavoglurant Australia AU2017261372 2036-05-05 See Plans and Pricing
Mavoglurant Canada CA3023278 2036-05-05 See Plans and Pricing
Mavoglurant China CN107847398 2036-05-05 See Plans and Pricing
Mavoglurant European Patent Office EP3452003 2036-05-05 See Plans and Pricing
Mavoglurant European Patent Office EP3981392 2036-05-05 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Moodys
McKesson
McKinsey
Mallinckrodt
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.